Micafungina Reig Jofre (Micafungin Sodium)

Micafungin sodium inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for constructing the β‑(1,3)‑D‑glucan polymer in the cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and fungal cell death while sparing human cells that lack this target.

The specific dose and infusion schedule of Micafungina Reig Jofre are determined by the prescribing clinician based on the patient’s infection type, severity, weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling when prescribing.

The safety of Micafungina Reig Jofre in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Micafungina Reig Jofre belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins generally have a favorable safety profile and are effective against many Candida species, including those resistant to azoles, but they are administered intravenously and are not suitable for oral therapy.

Micafungina Reig Jofre should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution, as these conditions can affect stability and potency.

The product is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein. The infusion rate and duration are set by the prescribing clinician, who will also monitor the patient for any infusion‑related reactions during and after administration.

Serious adverse events include hepatic failure, severe hypersensitivity reactions such as anaphylaxis, and rare but severe infusion‑related reactions. Clinicians should monitor liver function tests, watch for signs of allergic response, and be prepared to manage infusion reactions promptly.

Patients with a known hypersensitivity to micafungin sodium or any component of the formulation should not receive the drug. Caution is also advised for individuals with severe hepatic impairment, as they may be at higher risk for liver‑related adverse effects.